Pharmascience disposes of securities of BELLUS Health Inc.

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES AND NOT FOR DISSEMINATION IN THE UNITED STATES/

MONTREAL, June 5, 2017 /CNW Telbec/ - Pharmascience Inc. ("Pharmascience") announces that on May 29 and 30, 2017, it has disposed of ownership of an aggregate of 332,000 Shares of BELLUS, representing 0.5% of BELLUS' outstanding Shares. Pharmascience disposed of 132,000 Shares of BELLUS at an average price of $0.503 per Share and 200,000 Shares of BELLUS at an average price of $0.4521 per Share, for an aggregate consideration of $156,837.50. The Shares were disposed of through the Toronto Stock Exchange.

Prior to the transaction, Pharmascience held 6,350,638 Shares of BELLUS representing 9.5% of BELLUS' outstanding Shares. Immediately after the transaction, Pharmascience directly owns 6,018,638 Shares of BELLUS representing 9% of BELLUS' outstanding Shares.

Depending upon market conditions and other factors, Pharmascience may, from time to time, acquire or dispose of additional securities of BELLUS, in the open market, by private agreement or otherwise, or acquire interests in or enter into related financial instruments involving a security of BELLUS.

The head office address of BELLUS is 275 Armand-Frappier Blvd., Laval, Québec H7V 4A7.

About Pharmascience Inc.

Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with over 1 500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 60 countries. Ranked 57th among Canada's top 100 research & development (R&D) investors with over $44 million invested in 2015, Pharmascience Inc. is the 10th largest pharmaceutical company in Canada. Pharmascience Inc. has strong values which are based on the importance of investing in the personal development and life of employees and young people. At the beginning of 2017, Pharmascience Inc. has proudly been recognized for its investments by being selected as one of Canada's Top Employers for Young People and named as one of Montreal's best employers, as part of the Canada's Top 100 Employers project. Pharmascience Inc. has strong long-standing philanthropic ties with its communities, both locally and internationally. For more than 20 years, Pharmascience has been working through Health Partners International of Canada (HPIC) as the partner of choice to increase access to medicine. Pharmascience's total donations of essential medicine, is close to $60 million. Pharmascience Inc. is a leading manufacturer and marketer of prescription; generic, over-the-counter, and behind-the-counter products as well as FDA approved Canadian-made injectables. Pharmascience Inc. commercializes nearly 400 product families in 20 different dosage forms for over 2,000 products. In Canada alone, more than 45 million prescriptions a year are filled with Pharmascience products. For more information, please visit www.pharmascience.com

 

SOURCE Pharmascience Inc.

For further information: or to obtain a copy of the Early Warning Report filed by Pharmascience, please contact: Steeve Azoulay, Director, Public Affairs and Communications, Email: MediaInquiries@pharmascience.com, Phone: 514 340 7846 (Local), 1 866 229 8339 (Toll Free)

RELATED LINKS
pharmascience.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890